Biotech Blueprint
Subscribe
Sign in
Home
Notes
This Week in Biotech
Startup Spotlight
Deep Dives
Consulting
Archive
About
Latest
Top
Discussions
Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build — This Week in Biotech #76
Plus Novartis bets $12B on RNA delivery; Intensity’s tumor injection therapy stuns with 400% stock surge, and BridgeBio cements rare-disease momentum…
Oct 31
•
Katerina Roznik
4
1
Drug launch prices soar; mRNA shots linked to longer cancer survival — This Week in Biotech #75
ICER flags +51% net launch prices, Novo board shake-up, Tecentriq’s ctDNA-guided bladder success, Exelixis OS bump in colorectal cancer, and Ideaya…
Oct 24
•
Katerina Roznik
4
3
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
Moderna and BioNTech deploy AI-driven mRNA to target CMV, EBV, HSV, and personalized neoantigen cancer vaccines. These trials could redefine…
Oct 21
•
Katerina Roznik
and
The Biotech Capital Compass
6
5
Trump cuts IVF & Medicaid drug prices; Novo buys Omeros; Lilly's GLP-1 orforglipron shines — This Week in Biotech #74
Plus: BioCryst-Astria rounds out HAE, Praxis’ essential tremor pill succeeds in Phase 3, and Rocket’s LAD-I gene therapy returns to FDA review (Oct…
Oct 17
•
Katerina Roznik
4
Novo Nordisk Buys Akero & Regeneron’s Libtayo Wins Adjuvant CSCC Nod — This Week in Biotech #73
Repatha $239 cash launch, Dyne’s DM1 gains, Skye’s CB1 combo signal, Novavax-Sanofi EU handoff, Humacyte data + financing, Rocket pulls FA gene therapy…
Oct 10
•
Katerina Roznik
5
1
Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72
Plus $8B Genmab-Merus deal, Metsera's monthly GLP-1 score, Novavax/Sanofi & Vaxcyte/Thermo shore up U.S. capacity, and AbbVie sets U.K. Elahere price to…
Oct 3
•
Katerina Roznik
4
1
September 2025
Trump’s 100% Drug Tariff and a Huntington’s Breakthrough — This Week in Biotech #71
Palsonify cleared, Evkeeza label expanded, uniQure slows HD by ~75%, Pfizer buys Metsera, Cidara accelerates flu trial, ACIP shifts COVID guidance (Sept…
Sep 26
•
Katerina Roznik
2
1
ACIP votes, Roche–89bio deal, Regeneron’s FOP win — This Week in Biotech #70
Early-child MMRV change, Hep B/COVID votes pushed for today, $3.5B 89bio deal, Opzelura label expands, Regeneron breakthrough, Mounjaro goes pediatrics…
Sep 19
•
Katerina Roznik
3
The mRNA Revolution: Beyond COVID to Cancer, Flu & Herpes Vaccines
How Moderna and BioNTech are expanding from COVID into CMV, EBV, HSV, and next-gen flu, while scaling personalized cancer vaccines (part 1 of the mRNA…
Sep 18
•
Katerina Roznik
and
The Biotech Capital Compass
13
Novo’s Layoffs, Novartis’ $1.4B Buy, Pancreatic Cancer Progress — This Week in Biotech #69
Job cuts to refocus Wegovy/Ozempic; pacibekitug joins Novartis; Revolution Medicines shows early first-line activity; BioNTech/DualityBio scores an ADC…
Sep 12
•
Katerina Roznik
3
1
Ionis' Olezarsen Win, Novartis Licenses Arrowhead, CDC Vaccine Fight — This Week in Biotech #68
Ionis olezarsen’s Phase 3 in sHTG cuts triglycerides & pancreatitis. RFK Jr. reshapes ACIP again. Florida vaccine mandate rollback. United Therapeutics…
Sep 5
•
Katerina Roznik
3
August 2025
Monarez Fired, Novo’s srRNA Deal, ImmunityBio Wows in GBM — This Week in Biotech #67
Public health politics escalate as COVID rules shift, Novo backs Replicate’s next-gen RNA, and ImmunityBio posts 100% disease control in glioblastoma…
Aug 29
•
Katerina Roznik
5
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
